In this study we have demonstrated that CD4 CAR-T cells targeting CD19 play a crucial role in CRS development, being also actively involved in maintaining antitumor responses within the frame of B-ALL malignancy. This evidence concerns the gene CD4 and congenital rubella syndrome.